# Vitamin K AntagonISt, Factor Xa Inhibitor or No Anticoagulation in Atrial Fibrillation and DIalytic End-stage Renal DiseasE (VISIONAIRE)

Study · id `cardio:ct-nct06402851` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06402851](<https://clinicaltrials.gov/study/NCT06402851>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06402851

Browse, organ or system: Heart; Kidneys  
Browse, condition area: Stroke; Heart rhythm problems; Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1500 participants.

## Technical summary

Registry record NCT06402851. Randomized; single masking; primary purpose treatment. Start 2024-12-18 (actual); primary completion 2026-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1500 participants (planned count; ClinicalTrials.gov record NCT06402851, source copy `cardio:ctgov-nct06402851-2025-02-21`, retrieved 2026-10-26)
- Started: 2024-12-18 (actual) (ClinicalTrials.gov record NCT06402851, source copy `cardio:ctgov-nct06402851-2025-02-21`, retrieved 2026-10-26)
- Primary completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT06402851, source copy `cardio:ctgov-nct06402851-2025-02-21`, retrieved 2026-10-26)
- Completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT06402851, source copy `cardio:ctgov-nct06402851-2025-02-21`, retrieved 2026-10-26)
- Countries: Brazil (ClinicalTrials.gov record NCT06402851, source copy `cardio:ctgov-nct06402851-2025-02-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06402851-2025-02-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Vitamin K AntagonISt, Factor Xa Inhibitor or No Anticoagulation in Atrial Fibrillation and DIalytic End-stage Renal DiseasE (VISIONAIRE)
- Acronym: VISIONAIRE
- Condition: Atrium; Fibrillation
- Condition: Chronic Kidney Diseases
- Intervention (Drug): Anticoagulant Oral
- Lead sponsor: Hospital Sirio-Libanes
- Lead sponsor class: OTHER
- Collaborator: Daiichi Sankyo
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Anticoagulants (`cardio:anticoagulants`)
- Registry lists this organization as a collaborator: Daiichi Sankyo (`cardio:org-daiichi-sankyo`)

## Provenance

Content hash: 826238a91671ddb87282934495726631c183d4719a03b3b67fe55af25bd1e28b
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
